Humacyte (NASDAQ:HUMA) Upgraded at Barclays

Barclays upgraded shares of Humacyte (NASDAQ:HUMA) to a hold rating in a research report report published on Wednesday morning,Zacks reports.

Other research analysts have also recently issued research reports about the stock. Benchmark reduced their target price on shares of Humacyte from $2.00 to $1.00 and set a “speculative buy” rating for the company in a report on Thursday, August 13th. Wall Street Zen lowered shares of Humacyte from a “sell” rating to a “strong sell” rating in a report on Saturday, August 15th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Humacyte in a research report on Friday, October 2nd. BTIG Research reiterated a “buy” rating and set a $2.00 price objective on shares of Humacyte in a research note on Wednesday, August 12th. Finally, TD Cowen decreased their price objective on Humacyte from $1.50 to $1.25 and set a “buy” rating for the company in a report on Wednesday, June 17th. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Humacyte has a consensus rating of “Moderate Buy” and a consensus target price of $5.68.

Humacyte Price Performance

Shares of NASDAQ:HUMA opened at $0.41 on Wednesday. Humacyte has a twelve month low of $0.39 and a twelve month high of $1.90. The company’s 50 day moving average is $0.60 and its 200 day moving average is $0.76. The company has a current ratio of 6.21, a quick ratio of 5.74 and a debt-to-equity ratio of 2.07. The company has a market cap of $112.59 million, a PE ratio of -0.83 and a beta of 2.44.

Humacyte (NASDAQ:HUMA) last posted its quarterly earnings results on Wednesday, August 12th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.05). The business had revenue of $0.41 million for the quarter, compared to analysts’ expectations of $1.04 million. Humacyte had a negative return on equity of 983.32% and a negative net margin of 4,556.29%. On average, sell-side analysts forecast that Humacyte will post -0.40 EPS for the current year.

Hedge Funds Weigh In On Humacyte

Several large investors have recently made changes to their positions in HUMA. HBK Investments L P purchased a new position in Humacyte in the second quarter valued at $617,000. Miramontes Capital LLC acquired a new position in shares of Humacyte in the second quarter worth about $85,000. Alyeska Investment Group L.P. purchased a new stake in shares of Humacyte during the 2nd quarter worth about $4,700,000. Beacon Pointe Advisors LLC purchased a new stake in shares of Humacyte during the 2nd quarter worth about $28,000. Finally, Stonepine Capital Management LLC acquired a new stake in shares of Humacyte during the 2nd quarter valued at about $180,506. 44.71% of the stock is currently owned by institutional investors and hedge funds.

About Humacyte

Humacyte, Inc is a biotechnology company developing and manufacturing bioengineered human tissues for use in regenerative medicine. Its technology platform is designed to produce off-the-shelf, implantable tissues that can be stored and transported for use when needed, potentially reducing reliance on tissue obtained directly from patients or human donors.

The company’s primary product is SYMVESS, an acellular tissue-engineered vascular graft designed to replace or repair damaged blood vessels.